A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

Author： Gold Deborah T.   Martin Bradley C.   Frytak Jennifer R.   Amonkar Mayur M.   Cosman Felicia  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.3, 2007-03, pp. : 585-594

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical evaluation of osteoporosis and fracture risk in postmenopausal women

By McClung Betsy  

Clinical Review in Bone and Mineral Metabolism, Vol. 4, Iss. 1, 2006-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy

By Schousboe J.   Bauer D.   Nyman J.   Kane R.   Melton L.   Ensrud K.  

Osteoporosis International, Vol. 18, Iss. 2, 2007-02 ,pp. : 201-210

Springer Publishing Company

Access to resources Recommend Favorite

Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post‐menopausal osteoporosis

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 41, Iss. 5, 2016-10 ,pp. : 519-523

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women

By  

International Journal of User-Driven Healthcare (IJUDH), Vol. 1, Iss. 4, 2011-10 ,pp. : 61-76

IGI Global_journal

Access to resources Recommend Favorite

Alendronate Reduces the Excretion of Risk Factors for Calcium Phosphate Stone Formation in Postmenopausal Women with Osteoporosis

By  

Urologia Internationalis, Vol. 83, Iss. 2, 2009-09 ,pp. : 226-229

Karger

Access to resources Recommend Favorite